株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CAR-T細胞療法の世界市場の分析・予測:標的抗原・疾患区分・地域別

Global CAR T Cell Therapy Market, By Targeted Antigen, Therapeutic Application, and Geography - Trends, Analysis and Forecast till 2028

発行 Coherent Market Insights 商品コード 521311
出版日 ページ情報 英文 175 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.65円で換算しております。
Back to Top
CAR-T細胞療法の世界市場の分析・予測:標的抗原・疾患区分・地域別 Global CAR T Cell Therapy Market, By Targeted Antigen, Therapeutic Application, and Geography - Trends, Analysis and Forecast till 2028
出版日: 2018年05月31日 ページ情報: 英文 175 Pages
担当者のコメント
細胞治療、再生医療分野において、様々な製品が今後数年に上司が見込まれ、大幅な成長が見込まれるCAR-T細胞療法に特化したレポートが、Coherent Market Insightsよりリリースされました。標的抗原別(CD 19, 20, 22等)、各疾患区分別(急性リンパ性白血病 、非ホジキンリンパ腫等)に予測分析をまとめており、注目のレポートです。
概要

当レポートでは、世界のCAR-T細胞療法の市場を調査し、市場の定義と概要、市場成長への影響因子および市場機会の分析、関連法規制、産業動向、疫学/有病率/罹患率、標的抗原・疾患区分・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています

第1章 調査目的・前提因子

第2章 対象市場

  • レポート概要
  • エグゼクティブサマリー
  • COM (Coherent Opportunity Map)

第3章 市場力学・法規制・動向分析

  • 市場力学
    • 成長推進因子
    • 成長抑制因子
    • 市場機会
    • 法規制シナリオ
    • 産業動向
    • 疫学/有病率/罹患率
    • M&A
    • 新製品の承認・上市

第4章 市場分析・予測:標的抗原別

  • イントロダクション
    • 市場シェア実績・予測
    • 前年比成長分析・予測
    • 部門別分析
  • CD 19
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • CD 20
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • GD2
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • CD22
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • CD30
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • CD33
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • HER1
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • HER2
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • Meso
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • EGFRvlll
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • その他
    • イントロダクション
    • 市場規模・前年比成長率の予測

第5章 市場分析・予測:疾患区分別

  • イントロダクション
    • 市場シェア実績・予測
    • 前年比成長率の分析・予測
    • 部門別別動向
  • 急性リンパ性白血病
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • 慢性リンパ性白血病
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • 非ホジキンリンパ腫
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • 多発性骨髄腫
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • 膵癌
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • 神経芽細胞腫
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • 乳癌
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • 急性骨髄性白血病
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • 肝細胞癌
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • 大腸癌
    • イントロダクション
    • 市場規模・前年比成長率の予測
  • その他
    • イントロダクション
    • 市場規模・前年比成長率の予測

第6章 市場分析・予測:地域別

  • イントロダクション
    • 市場シェア実績・予測
    • 前年比成長率の分析・予測
  • 北米
    • 市場シェア実績・予測
    • 前年比成長率の分析・予測
    • 市場規模の推移と予測:標的抗原別
    • 市場規模の推移と予測:疾患区分別
  • 欧州
    • 市場シェア実績・予測
    • 前年比成長率の分析・予測
    • 市場規模の推移と予測:標的抗原別
    • 市場規模の推移と予測:疾患区分別
  • アジア太平洋
    • 市場シェア実績・予測
    • 前年比成長率の分析・予測
    • 市場規模の推移と予測:標的抗原別
    • 市場規模の推移と予測:疾患区分別
  • ラテンアメリカ
    • 市場シェア実績・予測
    • 前年比成長率の分析・予測
    • 市場規模の推移と予測:標的抗原別
    • 市場規模の推移と予測:疾患区分別
  • アフリカ
    • 市場シェア実績・予測
    • 前年比成長率の分析・予測
    • 市場規模の推移と予測:標的抗原別
    • 市場規模の推移と予測:疾患区分別
  • 中東
    • 市場シェア実績・予測
    • 前年比成長率の分析・予測
    • 市場規模の推移と予測:標的抗原別
    • 市場規模の推移と予測:疾患区分別

第7章 競合環境

  • ヒートマップ分析
  • 市場シェア分析
  • 企業プロファイル
    • Novartis International AG
    • Kite Pharma Inc.
    • Juno Therapeutics
    • Bellicum Pharmaceuticals, Inc.
    • Celgene Corporation
    • Cellectis
  • アナリストの見解
目次

Report Description

CAR-T cell therapy is a novel immunotherapy that helps to treat various types of cancers. CAR-T cells are genetically engineered cell receptors that are attached to the T-cells of the cancer patients and infused through the blood stream that activates immune system to kill the cancer causing cells in the body. The T-cells injected into the patient's body aids in reducing the risk of recurrence of tumor and thus, acts as a cure treatment for patients suffering with blood cancer. The CAR-T cell therapy is a solution to overcome the disease progression, identify the cancer causing cells, and kill them using body's own immune system and defense mechanism.

Market Dynamics

CAR-T cell therapy is expected to be an important development in cancer treatment and therapeutics industry due to its cost efficiency. Moreover, rising incidence of cancer is leading to high demand for its treatment. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases would be observed worldwide. Moreover, introduction of new therapies into the market is further expected to bolster growth of CAR-T cell therapy market. For instance, in October 2017, the U.S. Food and Drug Administration granted marketing approval to Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma. However, risks of side effects resulting in various neurological disorders is expected to hinder growth of the global CAR-T cell therapy market.

Key features of the study:

  • This report provides in-depth analysis of CAR-T cell therapy market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2017 - 2028), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global CAR-T cell therapy market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study includes Novartis International AG, Kite Pharma, Inc., Juno Therapeutics, Pfizer, Inc., Bellicum Pharmaceuticals, Inc., Celgene Corporation, Cellectis, and others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing strategies
  • The global CAR-T cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the CAR-T cell therapy market

Detailed Segmentation:

  • Global CAR-T Cell Therapy Market, by Targeted Antigen:
    • CD 19
    • CD 20
    • GD2
    • CD22
    • CD30
    • CD33
    • HER1
    • HER2
    • Meso
    • EGFRvlll
    • Others
  • Global CAR-T Cell Therapy Market, by Therapeutic Application:
    • Acute Lymphocytic Leukemia
    • Chronic Lymphocytic Leukemia
    • Non Hodgkin Leukemia
    • Multiple Myeloma
    • Pancreatic Cancer
    • Neuroblasta
    • Breast Cancer
    • Acute Myeloid Leukemia
    • Hepatocellular Carcinoma
    • Colorectal Cancer
    • Others
  • Global CAR-T Cell Therapy Market, by Region:
    • North America
      • By Targeted Antigen:
      • CD 19
      • CD 20
      • GD2
      • CD22
      • CD30
      • CD33
      • HER1
      • HER2
      • Meso
      • EGFRvlll
      • Others
      • By Therapeutic Application:
      • Acute Lymphocytic Leukemia
      • Chronic Lymphocytic Leukemia
      • Non Hodgkin Leukemia
      • Multiple Myeloma
      • Pancreatic Cancer
      • Neuroblasta
      • Breast Cancer
      • Acute Myeloid Leukemia
      • Hepatocellular Carcinoma
      • Colorectal Cancer
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Targeted Antigen:
      • CD 19
      • CD 20
      • GD2
      • CD22
      • CD30
      • CD33
      • HER1
      • HER2
      • Meso
      • EGFRvlll
      • Others
      • By Therapeutic Application:
      • Acute Lymphocytic Leukemia
      • Chronic Lymphocytic Leukemia
      • Non Hodgkin Leukemia
      • Multiple Myeloma
      • Pancreatic Cancer
      • Neuroblasta
      • Breast Cancer
      • Acute Myeloid Leukemia
      • Hepatocellular Carcinoma
      • Colorectal Cancer
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Targeted Antigen:
      • CD 19
      • CD 20
      • GD2
      • CD22
      • CD30
      • CD33
      • HER1
      • HER2
      • Meso
      • EGFRvlll
      • Others
      • By Therapeutic Application:
      • Acute Lymphocytic Leukemia
      • Chronic Lymphocytic Leukemia
      • Non Hodgkin Leukemia
      • Multiple Myeloma
      • Pancreatic Cancer
      • Neuroblasta
      • Breast Cancer
      • Acute Myeloid Leukemia
      • Hepatocellular Carcinoma
      • Colorectal Cancer
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Targeted Antigen:
      • CD 19
      • CD 20
      • GD2
      • CD22
      • CD30
      • CD33
      • HER1
      • HER2
      • Meso
      • EGFRvlll
      • Others
      • By Therapeutic Application:
      • Acute Lymphocytic Leukemia
      • Chronic Lymphocytic Leukemia
      • Non Hodgkin Leukemia
      • Multiple Myeloma
      • Pancreatic Cancer
      • Neuroblasta
      • Breast Cancer
      • Acute Myeloid Leukemia
      • Hepatocellular Carcinoma
      • Colorectal Cancer
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Targeted Antigen:
      • CD 19
      • CD 20
      • GD2
      • CD22
      • CD30
      • CD33
      • HER1
      • HER2
      • Meso
      • EGFRvlll
      • Others
      • By Therapeutic Application:
      • Acute Lymphocytic Leukemia
      • Chronic Lymphocytic Leukemia
      • Non Hodgkin Leukemia
      • Multiple Myeloma
      • Pancreatic Cancer
      • Neuroblasta
      • Breast Cancer
      • Acute Myeloid Leukemia
      • Hepatocellular Carcinoma
      • Colorectal Cancer
      • Others
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Targeted Antigen:
      • CD 19
      • CD 20
      • GD2
      • CD22
      • CD30
      • CD33
      • HER1
      • HER2
      • Meso
      • EGFRvlll
      • Others
      • By Therapeutic Application:
      • Acute Lymphocytic Leukemia
      • Chronic Lymphocytic Leukemia
      • Non Hodgkin Leukemia
      • Multiple Myeloma
      • Pancreatic Cancer
      • Neuroblasta
      • Breast Cancer
      • Acute Myeloid Leukemia
      • Hepatocellular Carcinoma
      • Colorectal Cancer
      • Others
      • By Country:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Novartis International AG *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Kite Pharma, Inc.
    • Juno Therapeutics
    • Pfizer, Inc.
    • Bellicum Pharmaceuticals, Inc.
    • Celgene Corporation
    • Cellectis
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet By Targeted Antigen
    • Market Snippet By Therapeutic Application
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Regulatory Scenario
    • Industry Trend
    • Epidemiology/Prevalence/Incidence
    • Merger and Acquisitions
    • New Product Approvals/Launch

4. Global Car T Cell Therapy Market, By Targeted Antigen, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • CD 19
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • CD 20
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • GD2
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • CD22
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • CD30
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • CD33
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • HER1
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • HER2
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Meso
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • EGFRvlll
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)

5. Global Car T Cell Therapy Market, By Therapeutic Application, 2017 - 2028 (USD Million)

  • Introduction
    • Market Share Analysis, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Acute Lymphocytic Leukemia
    • Introduction
    • Market Share Analysis, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, 2017 - 2028
  • Chronic Lymphocytic Leukemia
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Non Hodgkin Leukemia
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Multiple Myeloma
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Pancreatic Cancer
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Neuroblasta
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Acute Myeloid Leukemia
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Hepatocellular Carcinoma
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)

6. Global Car T Cell Therapy Market, By Regions, 2017 - 2028 (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Share Analysis, By Segments, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
    • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
  • Europe
    • Market Share Analysis, By Segments, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
    • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
  • Asia Pacific
    • Market Share Analysis, By Segments, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
    • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
  • Latin America
    • Market Share Analysis, By Segments, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
    • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
  • Africa
    • Market Share Analysis, By Segments, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
    • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
  • Middle East
    • Market Share Analysis, By Segments, 2017 and 2028 (%)
    • Y-O-Y Growth Analysis, By Segments, 2017 - 2028
    • Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
    • Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)

7. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
  • Company Profiles
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Kite Pharma Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Juno Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Bellicum Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Celgene Corporation
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Cellectis
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top